
Overview
Biotechna is an innovative biotechnology company focused on developing targeted therapies using nanotechnology, specifically for oncology. They have created a nanoparticle platform for the delivery of nucleic acids and small molecules, addressing various cancers such as breast, lung, and brain tumors. Additionally, they are advancing RNA and DNA-based products to target undruggable cancer types and enhance treatment effectiveness while reducing toxicity.
Financials
Revenue history (in k)
From the notes
| Current income tax (CIT due) | $0 | |
| Profit allocation | Loss to be covered | |
| Capital expenditure | $321,085 | |
| Planned capital expenditure (next year) | $251,130 | |
| R&D costs | $3,575,532 | |
| Contingent liabilities | Yes |
Filing timeliness
1 of 4 financial statements was filed late (for 2022, 3 days late). All were audited by a statutory auditor.
- 202509/07/2026
- 202415/07/2025
- 202310/07/2024
- 202218/07/2023
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Results vs industry
Industry
Offer
- Biotechnology testing
- Targeted therapy development
- Oncological testing
- RNA-based products
- DNA-based products
- Drug delivery systems
- Nanoparticle platforms
Websites
The site is available in: Polish and English.
- biotechna.comBIOTECHNA – SYNERGY to create hopeWordPress 3.7ElementorYoast SEOPPolylangCloudflare
Authorized Representatives
Manner of representation
In the case of a multi-member management board, each member of the management board is authorised to represent the company independently.
Supervisory board
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2019-07-04.
02 1090 1883 0000 0001 5934 4955
35 1090 1883 0000 0001 4771 8426
66 1090 1883 0000 0001 5596 6263
Debt
No entries in the National Debtors Register (KRZ).
MSiG notices
| Publication date | Event | |
|---|---|---|
| Feb 18, 2025 | Commercial Companies Code notice | |
| Nov 30, 2022 | Transformation registered |
Public aid
7 public aid cases recorded, with a total value of $25,512,091.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Dec 28, 2023 | Aid for research and development projects: industrial research | $9.3M$9,319,350 | Prezes Polskiej Agencji Rozwoju Przedsiębiorczości | |
| Dec 28, 2023 | Aid for research and development projects: experimental development | $1.3M$1,266,845 | Prezes Polskiej Agencji Rozwoju Przedsiębiorczości | |
| Sep 27, 2023 | Aid for research and development projects: industrial research | $6.9M$6,873,504 | Prezes Agencji Badań Medycznych |
European Funds
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2024-01-01 | KR2020 - Research and development of a first-in-class drug for use in non-small cell lung cancer | $11.1M$11,146,141 | European Funds for a Modern Economy |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
| BDO register entry | Active |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| JJP Biologics sp. z o.o. | $4,998,735.31 | jjpbiologics.com | ||
| Poltreg S.A. | $2,701,406.33 | poltreg.com | ||
| Captor Therapeutics S.A. | $2,286,539.43 | captortherapeutics.pl | ||
| Molecure S.A. | $1,889,300.60 | molecure.com | ||
| SDS Optic S.A. | $1,374,353.92 | sdsoptic.pl | ||
| Śląski Park Technologii Medycznych Kardio-Med Silesia sp. z o.o. | $969,037.30 | kmptm.pl | ||
| Nanogroup S.A. | $843,099.47 | nanogroup.eu | ||
| Oncotransfer sp. z o.o. | $704,767.72 | oncotransfer.pib-nio.pl | ||
| Famicordtx S.A. | $589,673.84 | famicordtx.com | ||
| Multiqure S.A. | $284,781.52 | purebiologics.com |
Change history
| Date | Event | |
|---|---|---|
| 2025-02-13 | Share capital increase (126,787.00 PLN → 127,883.00 PLN) | |
| 2025-02-13 | Name change (Bs Biotechna → Biotechna) | |
| 2024-11-06 | Share capital increase (125,220.00 PLN → 126,787.00 PLN) | |
| 2024-04-08 | Share capital increase (122,740.00 PLN → 125,220.00 PLN) | |
| 2023-07-21 | Share capital increase (117,900.00 PLN → 122,740.00 PLN) |
FAQ
Last updated: 2026-07-15